Benzinga | Aug 3, 2021 04:03PM EDT

Amgen Reaffirms FY21 Guidance; Sees Sales $25.8B-$26.6B vs $26.04B Est., Sees Adj. EPS $16-$17 vs $16.34 Est.

* 2021 total revenues guidance reaffirmed at $25.8-$26.6 billion; EPS guidance revised to $8.84-$9.90 on a GAAP basis, and reaffirmed at $16.00-$17.00 on a non-GAAP basis.